We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.40 | 0.55 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
27/4/2017 13:17 | ...Definitely a good top-up time imo. | someuwin | |
27/4/2017 08:16 | Seem to be a lot of sells this morning ummm do I top up I wonder ??? | typhoon | |
26/4/2017 20:51 | This is an exert from an email from the companies IR dept "The results for 2016 are due to be published in the next few weeks which will provide more information on the Company's cash position, but as the Company has no debt at the moment and strong positive data has just been delivered, it is in a relatively strong position with regards to funding options" GL has already stated there will be news within weeks (last week on justins podcast) on funding and we know they favour selling licenses which could generate significantly more than they need for REVIVE 2 and INSPIRE. He's prone to underselling and over delivering like results being in Q2, they were right at the start of easter. I think we may get funding news with the final results | drmaccers | |
26/4/2017 12:03 | Dip bought. Nice. More out and new folk in with higher average. A bit of consolidation and away we go.With the license news to resolve funding as the big kicker | drmaccers | |
26/4/2017 11:38 | Some traders exiting before the big next leg up | drmaccers | |
26/4/2017 10:43 | Had a quick look but couldn't find it. But then I can never find anything on Vox markets site. | someuwin | |
26/4/2017 08:34 | someuwin any link to the outcome of CEO discussion with Renshaw? | hjs | |
26/4/2017 07:10 | Big up day coming? | someuwin | |
25/4/2017 18:33 | Anyone where we are up to with revive2? When did it start and are we about half way through? | blueblood | |
25/4/2017 16:25 | hugger Iclaprim is already able to fight a limited range of 'superbugs' (i.e. bacteria resistant against most antibiotics) and I doubt there is any chance at all of it being effective against viruses. That's not to say it won't be a big money spinner in its own domain but I suspect you may have just got overexcited. | small crow | |
25/4/2017 15:20 | Martin Luke @martinjluke · 4 hours ago Graham Lumsden CEO of Motif Bio #MTFB discusses today's buy note from Renshaw exclusively on @voxmarkets | someuwin | |
25/4/2017 13:55 | Added a few more. | someuwin | |
25/4/2017 13:13 | Everybody on this thread seems to be missing some vital information disclosed by Lumsden and the relevant brokers about the huge possibilities of the Iclaprim molecule. From what I understand Motif are embarking on developing derivatives of this unique molecule to fight many present life threatening and dangerous infections and viruses. If this research is presently ongoing then this drug will not only treat skin and pulmonary infections but could be effectively altered to fight the super bugs we hear so much about. | hoggar | |
25/4/2017 10:52 | Bit of a slow one today | rizler | |
24/4/2017 19:31 | I currently have no sell price on this share. My holding is 37% up, but a quick look at the chart will show that it is only just over the 200sma. 50p had been my pencilled in trading target, but reviewing the chart I can't see why it won't get to 60.. and then indeed to the 2 year high at 70, which is another 70% rise from here. It's surely one of those situations where, given the stage 3 trial data, it's never been a better time to hold onto MTFB. Given success at REVIVE 2, it will surely get a lot, lot higher in due course, and the market must begin to discount that. Only IMHO, of course. | brucie5 | |
24/4/2017 19:08 | Very positive write up. Thanks for posting | pauliewonder | |
24/4/2017 18:05 | There will be valuation parity at some point in the journey, maybe now, maybe when the cash is rolling in | drmaccers | |
24/4/2017 16:35 | The current volume on the Nasdaq is circa 2600 ADR's, about $28k. Turnover on 'native Nasdaq' antibiotic co Tetraphase, for example, is about 40 times higher and they haven't even had any news recently, which illustrates what I mean about dual listings having their limitations. That is not say prospects aren't good here, just that you cannot rely on a dual Nasdaq listing to achieve valuation parity with Nasdaq stocks. | banshee | |
24/4/2017 15:43 | Experts at what. Scratching their backsides? Where so called experts are concerned I trust the very few independent experts when talking on world events - such as assessing chemical attacks - or not. On the stock market, I generally ignore self proclamed independent experts. There are none. Besides knowledge can be just as harmful as having none. | loverat | |
24/4/2017 15:20 | I hope your right, but I have seen many dual listed smallcap stocks, but I can't recall any attaining even remote parity with their Nasdaq peers, regardless of invariable expectations to the contrary. | banshee | |
24/4/2017 15:14 | We've successfully passed Phase 3 - that's the holy grail fot a pharma stock. Hugely de-risked now. Buy and hold for potential sales of $1bn a year. | someuwin | |
24/4/2017 15:00 | Too much short term optimism on here imo, alas. I say alas as I still have a few of these from around this price but haven't looked at the thread in ages. What happened to our resident industry expert who used to rubbish Motif at every opportunity? He was the guy who tipped Tetraphase instead which I put on my watch list and noticed it crashed 90% or so not long afterwards. Only experts can do this kind of thing. | banshee |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions